At Home Group Inc (HOME)
$6.18 1.13 (22.38%)
19:48 EDT HOME Stock Quote Delayed 30 Minutes
Previous Close $6.18
Market Cap 388.41M
PE Ratio 9.97
Volume (Avg. Vol.) 7.91M
Day's Range 5.05 - 6.33
52-Week Range 1.20 - 19.29
Dividend & Yield N/A (N/A)
HOME Stock Predictions, Articles, and At Home Group Inc News
- From InvestorPlace
- From the Web
At Home (HOME) earnings for the home decor retailer's fiscal third quarter of 2020 are hammering HOME stock hard on Tuesday.
Amazon, Facebook and Alphabet report earnings in the next two days, but a government investigation is stealing the headlines in the stock market today.
Snap, Tesla, MongoDB, Glu Mobile and At Home are our top stock trades for Friday. Check out the charts now.
At Home may be exploring a sale as the business is meeting with Bank of America to discuss potential buyers. HOME stock gained 8% on the news.
At Home (HOME) stock was sinking more than 20% Wednesday as the company's fourth-quarter earnings and guidance missed Wall Street's outlook.
All 5 of these names are setting up nicely for another pull higher -- watch for your opportunity to get in at a good price.
Consumer spending rises on a strong jobs market, rise in income, tax cuts and refunds. Compare Brokers....
3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)
At Home Group (HOME), HTG Molecular Diagnostics (HTGM) and iCAD (ICAD) all reported on their latest quarterly earnings after the bell Thursday.
Top Ranked Momentum Stocks to Buy for December 13th Compare Brokers...
From Talk Markets
From Analyst Ratings
Maxim Group analyst Jason McCarthy assigned a Buy rating to Co-Diagnostics (CODX – Research Report) today and set a price target of $30.00. The company’s shares closed last Wednesday at $17.35. According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.1% and a 45.5% success rate. McCarthy covers the Healthcare sector,
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Durect (DRRX – Research Report) and Co-Diagnostics (CODX – Research Report) with bullish sentiments. Durect (DRRX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Durect today and set a price target of $6.00. The company’s
Navellier RatingsPowered by Portfolio Grader